FibroGen, Inc.
FGEN
$0.2912
-$0.0269-8.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 104.25% | 15.45% | 14.26% | 54.59% | -314.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.25% | 15.45% | 14.26% | 54.59% | -314.77% |
| Cost of Revenue | -97.97% | -58.73% | -61.18% | -17.74% | 2.11% |
| Gross Profit | 101.70% | 176.39% | 119.97% | 80.29% | -725.20% |
| SG&A Expenses | 283.57% | -31.36% | -28.56% | -33.42% | -108.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -79.60% | -51.04% | -53.49% | -22.53% | -54.31% |
| Operating Income | 94.79% | 103.49% | 87.60% | 59.18% | -81.00% |
| Income Before Tax | 90.89% | 73.13% | 82.02% | 57.07% | -44.01% |
| Income Tax Expenses | 101.14% | -85.71% | -11.49% | -55.41% | -262.04% |
| Earnings from Continuing Operations | 90.88% | 73.14% | 82.27% | 57.07% | -43.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 131.98% | 73.14% | 82.27% | 57.07% | 15.03% |
| EBIT | 94.79% | 103.49% | 87.60% | 59.18% | -81.00% |
| EBITDA | 95.01% | 105.19% | 88.12% | 58.64% | -85.72% |
| EPS Basic | 131.38% | 73.75% | 82.65% | 58.93% | 19.26% |
| Normalized Basic EPS | 93.70% | 102.84% | 82.39% | 58.79% | -73.92% |
| EPS Diluted | 131.38% | 73.75% | 82.65% | 58.93% | 19.26% |
| Normalized Diluted EPS | 93.70% | 102.84% | 82.39% | 58.79% | -73.92% |
| Average Basic Shares Outstanding | 3.62% | 2.31% | 2.15% | 4.53% | 3.48% |
| Average Diluted Shares Outstanding | 3.62% | 2.31% | 2.15% | 4.53% | 3.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |